Status:
COMPLETED
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of tissue and blood in the laboratory from patients treated with ipilimumab with or without sargramostim may help doctors learn more about the effects of ipilimumab and sar...
Detailed Description
OBJECTIVES: * To compare the pathology of primary melanomas, melanoma metastases, and post-treatment melanoma metastases in relation to clinical outcomes for patients receiving ipilimumab plus sargra...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of measurable unresectable stage III or stage IV melanoma
- Treated with ipilimumab with or without sargramostim on clinical trial ECOG-E1608
- Primary tumor tissue and optional post-treatment biopsies of tumors from easily accessible tissues
- PATIENT CHARACTERISTICS:
- ECOG performance status 0 or 1
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
April 26 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 26 2013
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT01489423
Start Date
April 26 2013
End Date
May 26 2013
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.